Jason Efstathiou, Vice President at Radiation Oncology Institute (ROI) – The ASTRO Foundation, shared a post on X:
“Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER)
This video highlights NRG-GU015: ARCHER, a phase III, patient-centric, bladder-sparing trial now open to accrual. The trial asks whether ultra-hypofractionated RT (SBRT) over 5 treatments with chemotherapy can be safely and effectively adopted as a standard approach.
This has the potential to be an incredible advancement in treatment and care, and I’ll be sharing what I can about this study as it moves forward.
For more information, watch our video here.”
More posts featuring Jason Efstathiou.